Tumor necrosis factor alpha, or TNF alpha antibody products are widely used in cytokine and immunology research. TNF alpha is a pleiotropic ligand which plays an essential role in apoptosis, immune system development and the inflammatory response. We at Novus Biologicals have a number of TNF alpha antibody products in our catalog, which was recently enhanced by the addition of a new neutralizing TNF alpha antibody (NBP1-43235) . It is reactive against mouse, rat and rabbit tumour TNF-a, but not the human form of the antigen.
In nature, neutralizing antibodies defend cells from attack by antigens by neutralizing their biological effects. Normally, antibody binding flags antigens, which signal for their destruction – a response which may be inhibited. Neutralizing antibodies, however, specifically block the antigen’s effects. In 2003, Mark S. Freedman documented the effect of natural antibodies against IFN-beta, which was being investigated as a treatment for Multiple Sclerosis. He found that binding antibodies had no effect on the drug, whereas neutralizing antibodies blocked, or neutralized its action.
TNF alpha is expressed in a wide number of epithelial and immune cell types, and contains both a cytoplasmic and extracellular domain. Although essential for the inflammatory response, it is associated with a number of autoimmune disorders, including rheumatoid arthritis, Crohn's disease and psoriasis. TNF-a inhibitors, in the form of TNF alpha antibody drugs such as Infliximab and Adalimumab, have proven highly effective against these diseases, but with variable success.
Research has revealed the body can actually produce neutralizing antibodies against these therapeutic TNF alpha antibody preparations (as happened with IFN-beta) so evidently a lot more work needs to be done.
Novus Biologicals offers many TNF alpha reagents for your research needs including:
Comments
It's nearly impossible to find well-informed people in this particular subject, but you seem like you know what you're
talking about! Thanks